SUBSCRIBE
SUBSCRIBE
News   Policy

Roche Says Still Discussing Actemra with FDA

October 21, 2008 | 
1 min read
ZURICH, Oct 21 (Reuters) - Roche Holding AG is still discussing what additional information is required for approval of its Actemra rheumatoid arthritis drug with U.S. regulators, the Swiss company said on Tuesday.
Regulatory Europe
Food and Drug Administration (FDA) Roche
MORE ON THIS TOPIC
Insights
From fragile skin to living medicine: Lessons from RDEB
June 18, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Approvals
GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI
June 18, 2026
 · 
2 min read
 · 
Tristan Manalac
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Huntington’s disease
UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again
June 17, 2026
 · 
4 min read
 · 
Heather McKenzie
Podcast
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
June 17, 2026
 · 
2 min read
 · 
Jef Akst